|Day Low/High||6.11 / 6.60|
|52 Wk Low/High||2.20 / 8.20|
Trend continues by health providers to cover chromosomal microarray testing for recurrent pregnancy loss
Agreement expands access to CombiMatrix's test for women in the state of California
Data further validates CombiMatrix's microarray testing for miscarriage analysis and supports position as commercial and scientific leader in the $300 million annual U.S. market
High sensitivity and specificity PGS testing by Next Generation Sequencing supports healthy pregnancies and builds on prenatal diagnostics portfolio
Genetic testing now categorized by six additional health plans as medically necessary for the evaluation of pregnancy loss in specific cases
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.